Introduction: Tedizolid is a novel antibiotic of the class ofoxazolidinones. This review evaluates the published literature on the optic andperipheral neuropathy associated with short and prolonged administration oftedizolid.
Areas covered: A review of published data from 4 databases was conducted,regarding the development of optic and peripheral neuropathy in patients whoreceived tedizolid for short or prolonged duration. A total of 1,212 records werescreened; 33 were included in this review. No peripheral or optic neuropathycases were reported in 7 randomized controlled trials that studied tedizoliduse for a short course. In contrast, 2 cases with optic neuropathy (1 notsupported by objective findings) in 87 patients of the prospective studies wereidentified. Additionally, in a total of 277 patients who participated in the 6retrospective studies, 9 adverse events related to optic or peripheralneuropathy and 1 case with foot drop in 22 patients of the relevant casesreports were recorded.
Expert opinion: The available data suggests that the safety profile oftedizolid is favorable, especially when given for a short time. However, moreclinical studies are needed regarding its long-term use, given that the neurotoxicityinduced by oxazolidinones may be time and dose-dependent.
Keywords: Neurotoxicity; optic neuropathy; osteoarticular infection; oxazolidinones; peripheral neuropathy; protein synthesis inhibitor; skin infection; tedizolid.